Spyre Therapeutics, Inc. (SYRE) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Six clinical proof‑of‑concept readouts slated for 2026, reported cash runway into 2028 (~$757m cash/marketable securities) and a strong recent 21‑day move (~+26.8% with a one‑day +14% jump) give SYRE a clear event‑driven upside path; momentum traders can exploit this high‑risk setup ahead of Q2 SKYLINE Part A data and subsequent 2026 catalysts.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Very low leverage • High cash burn • No operating revenue SYRE has a strong cash and investment base with very low leverage but no revenue, large recurring losses, and negative free cash flow, leaving it dependent on financing to sustain operations.
Price Behavior
Key Price Behavior Insights: • Above last month SMA • Near resistance cap • Volatile rebound Support Level: $40.00–$41.50 Resistance Level: $50.44 SYRE is in a short‑term uptrend—closing $47.58 above the last month SMA (~$43.70) with a bullish RSI (~66) but faces resistance near $50.44 and key support around $40.00–$41.50, while recent sharp swings and a strong rebound from the $39.89 mid‑March low signal volatility risk.
Sentiment & News
Key News Insights: • Institutional buying • Equity hiring • Accelerated data Spyre Therapeutics is seeing concentrated institutional accumulation, targeted equity hiring incentives, positive clinical signals and accelerated timelines that may bring pivotal RA data forward to Q3 2026.
AI Summary
SYRE has transitioned into a near‑term, event‑driven investment—backed by a H2‑2028 cash runway and multiple 2026 Phase‑2 readouts that can materially re‑rate the stock, but investors should treat it as a binary catalyst trade and closely monitor POC efficacy/immunogenicity outcomes (and post‑readout dilution risk) as the decisive value driver.
Description
Spyre Therapeutics is a preclinical biotechnology firm developing monoclonal antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its lead program is an anti-α4β7 integrin IgG1 candidate, alongside antibody programs against TL1A and IL-23 and several combination regimens currently in preclinical evaluation. The company, incorporated in 2013 and renamed from Aeglea BioTherapeutics in November 2023, is based in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 23 | Mar 2 | SYRE | Spyre Therapeutics, Inc. | Six clinical proof‑of‑concept readouts slated for 2026, reported cash runway into 2028 (~$757m cash/marketable securities) and a strong recent 21‑day move (~+26.8% with a one‑day +14% jump) give SYRE a clear event‑driven upside path; momentum traders can exploit this high‑risk setup ahead of Q2 SKYLINE Part A data and subsequent 2026 catalysts. | Closed | -3.8% |